Cadrenal Therapeutics, Inc. Common Stock (CVKD) — Capital Reinvestment Ratio

Latest as of September 2022: 2.25x

Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a Capital Reinvestment Ratio of 2.25x as of September 2022, meaning it reinvests 2% of its operating cash flow ($1.01K) in capital expenditures ($2.28K). See CVKD net asset quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

2.25x
Capex / Operating Cash Flow

Operating Cash Flow

$1.01K
USD

Capital Expenditures

$2.28K
USD

Data as of

Sep 2022
Most recent filing

Annual Capital Reinvestment Ratio for Cadrenal Therapeutics, Inc. Common Stock (None–None)

Year-by-year Capital Reinvestment Ratio for Cadrenal Therapeutics, Inc. Common Stock from None to None. For live market cap and broader valuation context, see Cadrenal Therapeutics, Inc. Common Stock market cap and net worth.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow